PUBLIC COMPANY
saveZEALAND PHARMA
USupdated 3mo ago
community read0 votes
pipeline
0
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(0)
no pipeline products on record
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase3Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS
- phase2Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)
- phase3Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS
- EP1A Single and Multiple Ascending Dose Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP6590 in Participants With Normal Weight, Overweight and Obesity
- phase3Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon in Children With Congenital Hyperinsulinism
🐶 Hiring Signal
News
- Boehringer, Zealand’s obesity drug doesn’t elevate heart risk in key late-stage testThe Phase 3 results help clarify the safety profile of Zealand and Boehringer Ingelheim’s survodutide, but analysts do not think the drug will find utility beyond patients with liver-related risk f…biospace · 1d ago
- Should amylin have been obesity therapeutics’ primary target from the start?While GLP-1 medicines have become synonymous with weight loss, at least one expert thinks amylin would have been the go-to target if biopharma had been focused on the blockbuster indication 10 year…biospace · 23d ago
- Zealand pens up to $1.2B deal with Generate for AI-designed obesity, metabolic drugsObesity-focused Zealand Pharma is buying into Generate:Biomedicines’s generative AI platform to create new multispecific drug candidates.biospace · 27d ago
- Zealand inks up to $1.3B deal for AI-designed obesity treatmentsZealand Pharma said Tuesday it will develop new protein-based treatments for obesity and other metabolic diseases with the help of Generate Biomedicines’ AI technology. The Danish drugmaker is spen…endpoints · 28d ago
- Zealand inks $1.2B Generate pact to add multispecific proteins to obesity pipelineZealand Pharma is paying Generate Biomedicines $30 million upfront to collaborate on multispecific drug candidates for metabolic diseases. Milestones could bring the total value of the deal above $…fiercebiotech · 28d ago
- Roche extends China deal streak with $1B pact for RNAi obesity drugAn alliance with Rona Therapeutics adds to a particularly active stretch for Roche and makes the company the latest to bet on medicines that can lower levels of “visceral” fat.biopharma_dive · 28d ago
- Roche inks $1.2B deal with China's Rona to enter emerging ALK7 obesity raceRoche has committed $100 million in upfront and near-term payments to license Rona Therapeutics’ ALK7 drug candidate, joining Alnylam, Arrowhead, GSK and Novo Nordisk in an emerging obesity niche.fiercebiotech · 29d ago
- FDA review docs spark Revolution sell-off; Zealand diabetes data underwhelm analystsThe new disclosure suggested Rasonque might not be as broadly effective as previously thought. Elsewhere, Ultragenyx got a much-needed cash infusion and TCGX started a China-focused fund.biopharma_dive · 1mo ago
- Zealand, Roche topline a Phase 2 study for amylin drug, though Lilly remains an obstacleZealand Pharma and Roche rolled out some mid-stage data for their amylin drug in obesity and diabetes, hoping to compete with Eli Lilly. In a Phase 2 study, petrelintide reduced patients’ ...endpoints · 1mo ago
- Despite Zealand asset’s ‘intriguing’ weight loss, analysts underwhelmed by blood sugar numbersFor the second time in a week, Zealand Pharma’s weight loss pipeline has delivered mixed results, this time in a Phase 2 trial for the Roche-partnered asset petrelintide.biospace · 1mo ago
comments(0)
5-min edit window · permanent after that